The global gene therapy market is continuing to grow and is expected to reach $36.92 billion USD by 2027. The rising demand in the industry comes from the rising prevalence of genetic diseases, increasing investments in research and development for gene therapies, and growing regulatory approval of new gene products. But gene therapy is still an emerging field. Even as pharmaceutical companies look to bring their innovative treatment to clinical trials and eventually to market, the knowledge and expertise for commercialization is in short supply.
For pharmaceutical companies looking to outsource the development and manufacturing of their innovative treatment, it is crucial to partner with a gene therapy CDMO that can offer viral vector production, clinical trial management, and manufacturing scale-up capabilities. Expertise in these areas will ultimately make the drug development process more efficient and cost effective, resulting in faster time-to-market for new drugs and treatments. Explore the benefits of partnering with a reliable, experienced gene therapy CDMO and learn more about the invaluable support they can provide in taking your product to market.